Fewer than a tenth of individuals that would benefit from obesity jabs including Wegovy are able to get them, warns the World Health Organization as it releases its inaugural advice on the therapies.
Given over a billion people worldwide currently obese, it is urging broader and more equitable availability to this class of drugs.
According to estimates, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"The new guidelines affirms that excess weight is a chronic disease that can be addressed with comprehensive and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are significant barriers to universal access to the treatments that can aid individuals in losing considerable weight, notes the agency.
Skinny Jab Shortage
Even under the present most favorable case, the supply of such drugs would only suffice for about 100 million people – less than 10% of those who need them, per the health organization.
The recommendation urges governments and firms to widen availability, via approaches such as patent sharing.
A patent on a key compound – the core ingredient of Novo Nordisk's Wegovy – is due to expire in several countries in 2026.
How Weight-Loss Injections Work
These medications imitate a biological compound to slow digestion, curb appetite and boost the sense of being full so people reduce food intake.
People typically see weight reduction in the initial weeks of starting on the weekly injections.
Research indicates patients may regain a significant portion a year later of stopping the drug, as their usual hunger resume.
To be overweight or obese increases your likelihood for contracting medical conditions, such as diabetes, heart disease, brain attack, and some cancers.
Obesity concerns people in all nations and was responsible for millions of fatalities worldwide in 2024, as per the WHO.
